Skip to main content
Clinical Trials/DRKS00031548
DRKS00031548
Recruiting
Phase 4

observational comparative study: Intravitreal treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) with a bispecific antibody Vabysmo® (faricimab) vs. a classical anti-VEGF inhibitor Eylea® (aflibercept) in a treat-and-extend-regimen (FATE). - FATE

Augenklinik der Medizinischen Hochschule Hannover0 sites136 target enrollmentMarch 24, 2023

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
H35.30
Sponsor
Augenklinik der Medizinischen Hochschule Hannover
Enrollment
136
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 24, 2023
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Augenklinik der Medizinischen Hochschule Hannover

Eligibility Criteria

Inclusion Criteria

  • Consenting patients with macular edema, with underlying cause: neovascular age\-related macular degeneration, diabetes mellitus\-related maculopathy.
  • Minimum age 18 years, gender male/female/diverse.

Exclusion Criteria

  • Macular edema caused or influenced by an underlying cause other than neovascular age\-related macular degeneration or diabetes mellitus\-related maculopathy.
  • lack of capacity to consent.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Comparative study of the effect of intravitreal injection of bevacizumab versus simultaneous intravitreal injection of bevacizumab and triamcinolone acetonideRetinal vascular occlusions.Retinal vascular occlusions
IRCT20130812014333N185Kermanshah University of Medical Sciences58
Completed
Not Applicable
Evaluation of treatment options of central serous chorioretinopathyCentral Serous Chorioretinoathy.Central Serous Chorioretinopathy
IRCT2017041533448N1Vice chancellor for research, Zahedan University of Medical Sciences30
Completed
Not Applicable
Comparison of treatment response to intravitreal injection of triamcinolone, bevacizumab and combined form in patients with Central Retinal Vein Occlusion : A Randomized Clinical Trialthe efficacy of triamcinolone and bevacizumabwas measured in patients with Central Retinal Vein OcclusionBevacizumab&#44Intravitreal Injections&#44Retinal Vein Occlusion&#44Triamcinolone
TCTR20170612005rmia university of medical sciences90
Completed
Phase 4
Interindividual Comparison Trial – Two intraocular lenses with extended depth of focusCataractH26.9Cataract, unspecified
DRKS00010594niversitätsklinikum Knappschaftskrankenhaus Bochum GmbH Augenklinik43
Unknown
Not Applicable
Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on macular edema secondary to branch retinal vein occlusioMacular edema secondary to branch retinal vein occlusion
JPRN-UMIN000001546Shiga University of Medical Science, department of Ophthalmology60